Issue 1, 2014

Novel protein–protein interaction inhibitor of Nrf2–Keap1 discovered by structure-based virtual screening

Abstract

Herein we first reported hierarchical structure-based virtual screening utilizing the receptor–ligand binding model of Nrf2–Keap1. The most promising compound, 15, which is one of the most potent direct PPI inhibitors of Nrf2–Keap1 reported so far, can effectively disrupt the Nrf2–Keap1 interaction with the in vitro EC50 of 9.80 μM in the fluorescence polarization (FP) assay. 15 can also activate the Nrf2 transcription activity in the cell-based ARE–luciferase reporter assays in a dose-dependent manner. The compound can serve as a promising starting point for the discovery of potent inhibitors of Nrf2–Keap1 interaction.

Graphical abstract: Novel protein–protein interaction inhibitor of Nrf2–Keap1 discovered by structure-based virtual screening

Supplementary files

Article information

Article type
Concise Article
Submitted
26 Aug 2013
Accepted
28 Oct 2013
First published
30 Oct 2013

Med. Chem. Commun., 2014,5, 93-98

Novel protein–protein interaction inhibitor of Nrf2–Keap1 discovered by structure-based virtual screening

H. Sun, Z. Jiang, M. Zhang, M. Lu, T. Yang, Y. Pan, H. Huang, X. Zhang and Q. You, Med. Chem. Commun., 2014, 5, 93 DOI: 10.1039/C3MD00240C

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements